Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at $4.00.
Yi Chen has given his Buy rating due to a combination of factors including the strategic expansion of Vivani Medical’s collaboration with Okava Pharmaceuticals into veterinary medicine. This expansion involves the development of OKV-119, a GLP-1 therapy aimed at addressing weight management and cardiometabolic conditions in dogs, which could significantly enhance the utility and value of Vivani’s NanoPortal technology.
Additionally, the promising progress of Vivani’s human-focused projects, such as the NPM-115 implant, which has shown potential for improved medication adherence and efficacy, further supports the Buy rating. The positive preclinical data for NPM-139, demonstrating substantial weight loss and the potential for long-term dosing, also validates the versatility and promise of Vivani’s technology platform, contributing to the optimistic outlook for the company’s future developments.
In another report released on April 1, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.